Lori Ehrlich

11PUBLICATIONS
52CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumoursMolecular medicineCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

Nina Kim, E Dianne Pulte, Lori A Ehrlich

|Jan 09, 2025
Advancing drug development in myelodysplastic syndromes.

Alain Mina, Kathy L McGraw, Lea Cunningham

|Nov 09, 2024
An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.

Gulsum E Pamuk, Lori A Ehrlich

|Aug 01, 2024
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.

Gulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan

|Apr 03, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.

Nadia Howlader, Elad Sharon, Manami Bhattacharya

|Jan 23, 2023
Considerations for Drug Development in Myelodysplastic Syndromes.

Mikkael A Sekeres, Nina Kim, Amy E DeZern

Pageof 2

Frequent Collaborators

6 joint publications

R Angelo de Claro

5 joint publications

Kelly J Norsworthy

5 joint publications

Marc Theoret

4 joint publications

Nina Kim